Ali Amid

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/921967/publications.pdf

Version: 2024-02-01

26	605	840119	713013
papers	citations	11 h-index	21 g-index

27	27	27	766
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Thalassemia in Iran. Journal of Pediatric Hematology/Oncology, 2007, 29, 233-238.	0.3	181
2	International Medical Response to a Natural Disaster: Lessons Learned from the Bam Earthquake Experience. Prehospital and Disaster Medicine, 2006, 21, 141-147.	0.7	115
3	Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology,the, 2021, 8, e22-e33.	2.2	82
4	Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study. Lancet Haematology,the, 2019, 6, e144-e153.	2.2	37
5	An update on the prevalence of glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Tehran neonates. Clinical Biochemistry, 2004, 37, 241-244.	0.8	26
6	Thalassaemia in children: from quality of care to quality of life. Archives of Disease in Childhood, 2015, 100, 1051-1057.	1.0	22
7	Factor XIII deficiency in south-east Iran. Haemophilia, 2004, 10, 470-472.	1.0	19
8	Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis. Blood, 2016, 127, 1208-1211.	0.6	16
9	Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study. Blood, 2016, 128, 3633-3633.	0.6	15
10	Improving Outcomes in Children with Sickle Cell Disease: Treatment Considerations and Strategies. Paediatric Drugs, 2014, 16, 255-266.	1.3	14
11	Risk factors for hyperferritinemia secondary to red blood cell transfusions in pediatric cancer patients. Pediatric Blood and Cancer, 2013, 60, 1671-1675.	0.8	13
12	Multi-label Classification of Anemia Patients. , 2015, , .		12
13	Outcomes of haemoglobin Bartâ€™s hydrops fetalis following intrauterine transfusion in Ontario, Canada. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, 106, 51-56.	1.4	9
14	Screening for Thalassemia Carriers in Populations with a High Rate of Iron Deficiency: Revisiting the Applicability of the Mentzer Index and the Effect of Iron Deficiency on Hb A₂Levels. Hemoglobin, 2015, 39, 141-143.	0.4	8
15	Iron overload in transfusion-dependent survivors of hemoglobin Bartâ€™s hydrops fetalis. Haematologica, 2018, 103, e184-e187.	1.7	8
16	Hb S/Â+-thalassemia due to Hb sickle and a novel deletion of DNase I hypersensitive sites HS3 and HS4 of the Â locus control region. Haematologica, 2015, 100, e166-e168.	1.7	6
17	Consensus statement for the perinatal management of patients with Î± thalassemia major. Blood Advances, 2021, 5, 5636-5639.	2.5	6
18	Evans Syndrome Secondary to HIV Infection. Journal of Pediatric Hematology/Oncology, 2013, 35, 490.	0.3	4

#	Article	IF	Citations
19	Optimizing transfusion therapy for survivors of Haemoglobin Bart's hydrops fetalis syndrome: Defining the targets for <scp>haemoglobinâ€H</scp> fraction and â€œfunctionalâ€•haemoglobin level. British Journal of Haematology, 2022, 197, 373-376.	1.2	4
20	COVID Vaccination Rates in Children and Adults with Sickle Cell Disease in British Columbia, Canada. Blood, 2021, 138, 3034-3034.	0.6	3
21	Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload. Acta Haematologica, 2019, 141, 256-260.	0.7	2
22	Drisapersen associated with elevated serum factor VIII levels in Duchenne muscular dystrophy. Neurology, 2020, 94, 538-540.	1.5	2
23	Presentation of Central Nervous System Tumors. , 2015, , 3-7.		1
24	Evans Syndrome Secondary to HIV Infection. Journal of Pediatric Hematology/Oncology, 2013, 35, 491.	0.3	0
25	Immune tolerance induction using Fcâ€fusionâ€protein recombinant factor IX in severe haemophilia B. Haemophilia, 2021, 27, e776-e779.	1.0	0
26	Compound Heterozygosity for Hb S and a Novel Deletion of Dnase I Hypersensitivity Sites HS3 and HS4 of Î²-Globin Locus Control Region Results in Hb S/Î²+-Thalassemia Phenotype. Blood, 2014, 124, 2692-2692.	0.6	0